Tula, Russian Federation
Russian Federation
Russian Federation
employee
Russian Federation
employee
Tula, Russian Federation
employee
Russian Federation
UDC 61
Small cell lung cancer accounts for almost 13% of all newly diagnosed lung cancer cases. Most patients have an aggressive course of the disease, and without treatment, the average survival is from 2 to 4 months. Brain metastases are common in this disease. At the time of diagnosis, at least 18% of patients have metastases in the brain if properly examined. Preventive irradiation of the brain is now a commonly accepted part of the treatment of both localized and widespread small cell lung cancer. However, the data confirming its effectiveness is based on meta-analyses of studies conducted before the use of generally accepted and currently mandatory methods for determining the true prevalence of the disease (for example, brain MRI and PET/CT). Currently, there is increasing evidence that in modern realities, subject to careful examination and proper staging, the option of preventive brain irradiation seems to be ineffective, and modern immunotherapy can provide better cerebral control with less potential toxicity.
small cell lung cancer, brain metastases, radiation therapy, preventive brain irradiation
1. Bahmutskiy N.G., Porhanov V.A., Bodnya V.N. i dr. Melkokletochnyy rak legkogo. Medicinskiy vestnik Yuga Rossii. 2017. T. 8, № 4. S. 6-13.
2. Zlokachestvennye novoobrazovaniya v Rossii v 2023 godu (zabolevaemost' i smertnost') / pod red. A.D. Kaprina [i dr.] M.: MNIOI im. P.A. Gercena − filial FGBU «NMIC radiologii» Minzdrava Rossii, 2024. ill. 276 s.
3. Zubec A.N. Kolichestvennye ocenki v istorii (instrumenty dlya kliometrii). Finansovyy universitet pri pravitel'stve RF, 2014.
4. Kashirskaya E.N. Lomonosov i medicina (Gazeta «Moskovskiy universitet», №26) [Elektronnyy resurs]. – URL: https://www.msu.ru/lomonosov/science/med.html
5. Klinicheskie rekomendacii obscheros. nac. soyuza «Associaciya onkologov Rossii», obscheros. obsch. organizacii «Rossiyskoe obschestvo klin. onkologii». Zlokachestvennoe novoobrazovanie bronhov i legkogo. M., 2022. 104 s.
6. Rak legkogo. Pod red. K.K. Laktionova i V.V. Bredera. M.: «GRANAT», 2020.
7. Tyurin V.I. Izuchenie prediktivnyh molekulyarno-geneticheskih markerov effektivnosti terapii raka legkogo: dissertaciya ... kandidata medicinskih nauk: 3.1.6. Sankt-Peterburg 2021
8. Harchenko V.P., Kuz'mina I.V. Rak legkogo. Fundamental'nye problemy i klinicheskie perspektivy. Rukovodstvo dlya vrachey. M: Medicina. 1994. 479 s.
9. Chubenko V.A., Bychkov M. B., Den'gina N. V. i dr. Melkokletochnyy rak legkogo. Prakticheskie rekomendacii RUSSCO, chast' 1.1. Zlokachestvennye opuholi 2024;14(3s2):105–114.
10. Arriagada R., Le Chevalier T., Rivie`re A. et al. Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: analysis of 505r andomized patients. Ann Oncol. 2002;13:748-754.
11. Auperin A., Arriagada R., Pignon J.P. et al; Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341:476-484.
12. Aur R.J., Verzosa M.S., Hustu H.O. et al. Response to combination therapy after relapse in childhood acute lymphocytic leukemia. Cancer. 1972 Aug;30(2):334-8. doi:https://doi.org/10.1002/1097-0142(197208)30:2<334:aid-cncr2820300205>3.0.co;2-6. PMID: 4538148.
13. Borzelleca J.F. Paracelsus: Herald of Modern Toxicology // Toxicological Sciences. 2000. Vol. 53. № 1. P. 2-4.
14. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi:https://doi.org/10.3322/caac.21834. Epub 2024 Apr 4. PMID: 38572751.
15. Brewer L.A. Historical notes on lung cancer before and after Graham’s successful pneumonectomy in 1933 // The American Journal of Surgery. – 1982. – Vol. 143. – № 6. – P. 650-659.
16. Choi M., Lee Y, Moon S.H. et al. Effect of accurate staging using positron emission tomography on the outcomes of prophylactic cranial irradiation in patients with limited stage small-cell lung cancer. Clin Lung Cancer. 2017;18:77-84.
17. Chu, Xiao; Zhu, Zhengfei. Prophylactic cranial irradiation in small cell lung cancer: an update. Current Opinion in Oncology 35(1):p 61-67, January 2023. | DOI:https://doi.org/10.1097/CCO.0000000000000910.
18. David A.R., Zimmerman M.R. Cancer: an old disease, a new disease or something in between? // Nature Reviews. Cancer. 2010. Vol. 10. P. 728-733.
19. De Ruysscher D., Dingemans A.C., Praag J. et al. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11/DLCRG-02 study. J Clin Oncol. 2018;36:2366-2377.
20. De Ruysscher D., Pijls-Johannesma M., Vansteenkiste J. et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006; 17:543–552.
21. Dingemans, A. M. C., Fruh M., Ardizzoni A. et al. ESMO Guidelines Committee (2021). Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(7), 839-853. https://doi.org/10.1016/j.annonc.2021.03.207.
22. Einhorn L.H., Bond W.H., Joe B.T. et al. Long-term results in combined-modality treatment of small cell carcinoma of the lung. 1978;5(3):309–313 a. Semin Oncol. 1978;5:309-313.
23. Fornaciari G. Histology of ancient soft tissue tumors: A review // International Journal of Paleopathology. 2017. P. 64-76.
24. Gaeta R. Cancer in the Renaissance court of Naples / R. Gaeta, V. Giuffra, G. 2017 Aug;18(8):e432. doi:https://doi.org/10.1016/S1470-2045(17)30464-3.
25. Govindan R., Page N., Morgensztern D. et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006;24:4539-4544.
26. Jett J.R., Schild S.E., Kesler K.A. et al. Treatment of Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. In Chest, Vol. 143. 2013;e400S-e419S.
27. Kalemkerian G.P., Loo B.W., Akerley W. et al. NCCN guidelines insights: small cell lung cancer, version 2.2018. J Natl Compr Canc Netw. 2018;16:1171-1182.
28. Rodriguez-Canales J., Parra-Cuentas E., Wistuba I.I. Diagnosis and Molecular Classification of Lung Cancer // Cancer Treatment and Research. 2016. Vol. 170. P. 25-46.
29. Seute T., Leffers P., ten Velde G.P. et al. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer. 2008;112:1827-1834.
30. Seute T., Leffers P., ten Velde GPM, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004;100:801-806.
31. Slotman B., Faivre-Finn C., Kramer G. et al. EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357(7):664–72.
32. Slotman B.J., Mauer M.E., Bottomley A. et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. [erratum: J Clin Oncol. 2009;27:1002] J Clin Oncol. 2009;27:78-84.
33. Small Cell Lung Carcinoma: Staging, Imaging, and Treatment Considerations / B.W. Carter [et al.] // RadioGraphics. 2014. Vol. 34, № 6. P. 1707-1721.
34. Sun A., Bae K., Gore E.M. et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2011;29:279-286.
35. Takahashi T., Yamanaka T., Seto T. et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a mul- ticentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663-671.
36. Version 2.2025, 09/05/24 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.
37. Witschi H. A Short History of Lung Cancer // Toxicological Sciences. 2001. Vol. 64, № 1. P. 4-6.
38. Wu A.J., Gillis A., Foster A. et al. Patterns of failure in limited-stage small cell lung cancer: implications of TNM stage for prophylactic cranial irradiation. Radiother Oncol. 2017;125:130-135.
39. Xu J., Yang H., Fu X. et al. Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. Journal of Thoracic Oncology. 2017; 12:347-363.
40. Yoda S., Dagogo-Jack I., Hata A.N. Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities // Pharmacology & Therapeutics. 2019. Vol. 193. P. 20-30.
